Sirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic cell transplantation: a single institution experience

Saved in:
Bibliographic Details
Published inBone marrow transplantation (Basingstoke) Vol. 50; no. 11; pp. 1487 - 1489
Main Authors Nelson, R, Shapiro, J F, Perkins, J B, Kim, J, Nishihori, T, Pidala, J, Ayala, E, Locke, F L, Field, T, Mishra, A, Riches, M, Betts, B, Perez, L, Yue, B, Ochoa-Bayona, J L, Alsina, M, Fernandez, H, Anasetti, C, Kharfan-Dabaja, M A
Format Journal Article
LanguageEnglish
Published England Nature Publishing Group 01.11.2015
Subjects
Adult
Aged
Antibiotic prophylaxis
Antilymphocyte serum
Antilymphocyte Serum - therapeutic use
Bone marrow
Complications and side effects
Female
Globulins
Graft rejection
Graft Survival
Graft vs Host Disease - prevention & control
Graft-versus-host reaction
Health aspects
Hematopoietic Stem Cell Transplantation
Histocompatibility
Histocompatibility antigen HLA
HLA antigens
Humans
Immunosuppressive Agents - therapeutic use
Male
Methods
Middle Aged
Prevention
Prophylaxis
Rapamycin
Retrospective Studies
Sirolimus - therapeutic use
Stem cell transplantation
T-Lymphocytes - immunology
Tacrolimus
Tacrolimus - therapeutic use
Thymocytes
Transplantation
Young Adult
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ISSN:0268-3369
1476-5365
DOI:10.1038/bmt.2015.192